VFA
RNTX

Valeo Financial Advisors’s Rein Therapeutics RNTX Stock Holding History

Valeo Financial Advisors’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50
Closed -$1K – 1888
2021
Q1 		$1K Buy
+50
New +$1.71K ﹤0.01% 1964

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Valeo Financial Advisors's RNTX Position: Q2 2021 in Review

Valeo Financial Advisors sold out of Rein Therapeutics (RNTX) in Q2 2021, closing a stake of 50 shares — an estimated $1K sold.

Valeo Financial Advisors first reported a position in RNTX in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 47 funds tracked by Wall St. Rank hold RNTX as of Q2 2021.

  • Valeo Financial Advisors reported no remaining Rein Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 50 Rein Therapeutics shares in Q2 2021, an estimated $1K.
  • Valeo Financial Advisors first reported a position in Rein Therapeutics in Q1 2021 and held it in 1 quarter.
  • Valeo Financial Advisors's Rein Therapeutics position peaked at $1K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.